Patents by Inventor W. Scott Willett
W. Scott Willett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230058309Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.Type: ApplicationFiled: March 15, 2022Publication date: February 23, 2023Inventors: W. Scott Willett, Richard J. Caimi
-
Publication number: 20210179679Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.Type: ApplicationFiled: July 28, 2020Publication date: June 17, 2021Inventors: W. Scott Willett, Richard J. Caimi
-
Publication number: 20200369735Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.Type: ApplicationFiled: December 31, 2019Publication date: November 26, 2020Inventors: W. Scott Willett, Richard J. Caimi
-
Publication number: 20180044387Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.Type: ApplicationFiled: April 20, 2017Publication date: February 15, 2018Inventors: W. Scott Willett, Richard J. Caimi
-
Patent number: 9556246Abstract: Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.Type: GrantFiled: November 6, 2012Date of Patent: January 31, 2017Assignee: Promedior, Inc.Inventor: W. Scott Willett
-
Patent number: 9296800Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.Type: GrantFiled: June 4, 2010Date of Patent: March 29, 2016Assignee: Promedior, Inc.Inventors: W. Scott Willett, Richard J. Caimi
-
Publication number: 20140302024Abstract: Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein.Type: ApplicationFiled: March 24, 2014Publication date: October 9, 2014Applicant: PROMEDIOR, INC.Inventors: Mark L. Lupher, JR., W. Scott Willett
-
Publication number: 20130064866Abstract: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Applicant: Promedior, Inc.Inventors: W. Scott Willett, Richard J. Caimi, Lynne Anne Murray
-
Patent number: 8329659Abstract: Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.Type: GrantFiled: June 17, 2010Date of Patent: December 11, 2012Assignee: Promedior, Inc.Inventor: W. Scott Willett
-
Publication number: 20100323970Abstract: Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.Type: ApplicationFiled: June 17, 2010Publication date: December 23, 2010Applicant: Promedior, Inc.Inventor: W. Scott Willett
-
Publication number: 20100317596Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.Type: ApplicationFiled: June 4, 2010Publication date: December 16, 2010Inventors: W. Scott Willett, Richard J. Caimi
-
Publication number: 20100266643Abstract: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.Type: ApplicationFiled: April 1, 2010Publication date: October 21, 2010Inventors: W. Scott Willett, Richard J. Caimi, Lynne Anne Murray
-
Publication number: 20100113743Abstract: The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: October 23, 2009Publication date: May 6, 2010Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Susann Taudte, W. Scott Willett, Matthew Kalo, Robert J. Bayer
-
Patent number: 5322930Abstract: An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.Type: GrantFiled: November 12, 1992Date of Patent: June 21, 1994Assignee: Scios Nova Inc.Inventors: S. Joseph Tarnowski, Sandra Hilliker, W. Scott Willett
-
Patent number: 5202239Abstract: An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.Type: GrantFiled: August 7, 1990Date of Patent: April 13, 1993Assignee: Scios Nova Inc.Inventors: S. Joseph Tarnowski, Sandra Hilliker, W. Scott Willett